AAAAAA

   
Results: 1-7 |
Results: 7
Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment
Authors: Atencio, IA Avanzini, JB Johnson, D Neuteboom, S Vaillancourt, MT Nielsen, LL Hajian, G Sutjipto, S Sugarman, BJ Philopena, J McAllister, DL Beltran, JC Nodelman, M Ramachandra, M Wills, KN
Citation: Ia. Atencio et al., Enhanced apoptotic activity of a p53 variant in tumors resistant to wild-type p53 treatment, MOL THER, 4(1), 2001, pp. 5-12
Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
Authors: Jen, JF Glue, P Ezzet, F Chung, C Gupta, SK Jacobs, S Hajian, G
Citation: Jf. Jen et al., Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C, CLIN PHARM, 69(6), 2001, pp. 407-421
Population pharmacokinetics of temozolomide in cancer patients
Authors: Jen, JF Cutler, DL Pai, SM Batra, VK Affrime, MB Zambas, DN Heft, S Hajian, G
Citation: Jf. Jen et al., Population pharmacokinetics of temozolomide in cancer patients, PHARM RES, 17(10), 2000, pp. 1284-1289
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
Authors: Shi, B Yaremko, B Hajian, G Terracina, G Bishop, WR Liu, M Nielsen, LL
Citation: B. Shi et al., The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo, CANC CHEMOT, 46(5), 2000, pp. 387-393
Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C
Authors: Jen, JF Glue, P Gupta, S Zambas, D Hajian, G
Citation: Jf. Jen et al., Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C, THER DRUG M, 22(5), 2000, pp. 555-565
Derivation and initial characterization of a mouse mammary tumor cell linecarrying the polyomavirus middle T antigen: Utility in the development of novel cancer therapeutics
Authors: Nielsen, LL Gurnani, M Shi, B Terracina, G Johnson, RC Carroll, J Mathis, JM Hajian, G
Citation: Ll. Nielsen et al., Derivation and initial characterization of a mouse mammary tumor cell linecarrying the polyomavirus middle T antigen: Utility in the development of novel cancer therapeutics, CANCER RES, 60(24), 2000, pp. 7066-7074
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models
Authors: Nielsen, LL Shi, B Hajian, G Yaremko, B Lipari, P Ferrari, E Gurnani, M Malkowski, M Chen, JP Bishop, WR Liu, M
Citation: Ll. Nielsen et al., Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models, CANCER RES, 59(23), 1999, pp. 5896-5901
Risultati: 1-7 |